Crinetics Pharmaceuticals, Inc. — Form 10-Q
Filed August 3, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 8/100
What the filing says
R. Scott Struthers (CEO) and Tobin Schilke (CFO) have certified the June 30, 2026 quarterly report pursuant to Sarbanes-Oxley Sections 302 and 906. Both officers attest that disclosure controls, internal financial controls, and financial statements fairly present the company's condition and operations as of the filing date (August 3, 2026). No material weaknesses, deficiencies, or fraud are disclosed.
Why this rating
Routine SOX certifications; standard periodic compliance disclosure with no substantive business changes, transactions, or control failures disclosed.
See more from August 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.